QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Drucker, L. Articles by Lishner, M. Search for Related Content PubMed PubMed Citation Articles by Drucker, L. Articles by Lishner, M.

Thalidomide Down-Regulates Transcript Levels of GC-Rich Promoter Genes in Multiple Myeloma

Oncogenetic (L.D., O.U., T.T, S.Y., M.L., M.L.) and Hematology (H.S., J.R.) Laboratories and Department of Medicine (M.L., M.L.), Sapir Medical Center, Kfar-Saba, Israel; and Tel-Aviv University, Tel-Aviv, Israel (M.L., M.L.)

Thalidomide (Thd), a potent teratogen, was shown to have therapeutic potential in cancer, primarily in multiple myeloma (MM), yet its mechanism of action has not been elucidated. It was recently suggested that its teratogenicity is derived from interference in expression of genes regulated by GC-rich promoters by blocking the binding of SP1 transcription factor to its motif. We explored the validation of the proposed model by focusing on potential molecular targets associated with MM pathogenesis. Cell lines RPMI 8226, U266, and ARH-77 were exposed for 24 h to racemic Thd and analyzed for apoptosis, membranal expression of CD29 and CD63, transcript level of hTERT, CD63, and IGFI-R (characterized by GC-rich motifs) and telomerase activity. Analysis of an hTERT core promoter reporter gene expression [enhanced green fluorescent protein (EGFP)] in transiently transfected RPMI 8226 incubated with racemic and steric (±)-enantiomers of Thd was performed. A consistent reduction (10–40%) in transcript levels of all three assayed genes in all three cell lines was demonstrated in the presence of racemic Thd. Significant reduction of EGFP was demonstrated in cells transfected with hTERT reporter gene and treated with racemic and (S)-Thd. Our results show that Thd's antimyeloma activity can be ascribed to the same mechanism responsible for its teratogenic effect and that the inhibition of GC-rich promoter genes is mostly attributed to the S-racemate. Indeed, this selectivity delineates GC-rich promoter genes as a unique group eligible for specific drug targeting.

Address correspondence to: Dr. Liat Drucker, Oncogenetic Laboratory, Sapir Medical Center, Meir Hospital, Kfar Sava, 44281, Israel. E-mail: druckerl{at}clalit.org.il